Skip to main content


Latest articles

13-06-2019 | Rheumatology | News | Article

Upadacitinib and adalimumab switching beneficial in refractory RA

Patients with rheumatoid arthritis who initially fail to respond to either the Janus kinase inhibitor upadacitinib or the tumor necrosis factor inhibitor adalimumab can benefit from switching to the alternative drug, post-hoc analysis of the SELECT-COMPARE study suggests.

13-06-2019 | Rheumatology | News | Article

Further support for tocilizumab use in giant cell arteritis

More than a third of patients with giant cell arteritis remission who discontinue tocilizumab treatment after 1 year remain in clinical remission for a further 2 years, suggest follow-up results from the GiACTA trial.

12-06-2019 | Rheumatology | News | Article

Tildrakizumab shows promise for PsA

Phase IIb trial results reported at the EULAR 2019 congress in Madrid, Spain, suggest that tildrakizumab may be a promising treatment option for people with psoriatic arthritis.

10-06-2019 | Rheumatology | News | Article

European recommendations for the diagnosis of gout issued

EULAR has issued eight updated evidence-based recommendations to guide the diagnosis of gout.

07-06-2019 | Rheumatology | News | Article

Predictors of sustained remission/LDA in anti-TNF-treated RA patients identified

Sustained remission and low disease activity remain uncommon in patients with rheumatoid arthritis receiving anti-tumor necrosis factor therapy but can be predicted by several factors, shows an analysis published in Rheumatology.

07-06-2019 | Rheumatology | News | Article

Integrated analysis supports safety profile of abatacept in RA

A pooled analysis of data from nine randomized placebo-controlled trials suggests that abatacept has a favorable safety profile among patients with rheumatoid arthritis.

06-06-2019 | Rheumatology | News | Article

Atherosclerotic plaque burden may aid CV risk prediction in psoriatic disease

Increased atherosclerotic plaque burden, as estimated by carotid ultrasound, is associated with an increased risk for cardiovascular events in patients with psoriatic disease, Canadian researchers report.

04-06-2019 | Rheumatology | News | Article

Support for TNF inhibitor dose reduction in RA patients with low disease activity

Dose reduction of tumor necrosis factor (TNF) inhibitors may be an appropriate strategy for rheumatoid arthritis patients who achieve low disease activity while receiving full doses of the agents, report the authors of a Cochrane systematic review.

03-06-2019 | Rheumatology | News | Article

IL-6 receptor inhibition may induce bone erosion repair in RA

Patients with early rheumatoid arthritis who are treated with the interleukin-6 receptor inhibitor tocilizumab experience more pronounced repair of bone erosions than those given adalimumab plus methotrexate, indicate findings from the REBONE study.

31-05-2019 | Rheumatology | News | Article

Metformin may slow knee OA progression in people with obesity

Metformin use may protect against knee cartilage damage in obese people with knee osteoarthritis, suggests an analysis of Osteoarthritis Initiative participants.

30-05-2019 | Rheumatology | News

FDA approves first diagnostic test for joint replacement infections

The US FDA has approved a diagnostic test to aid detection of infections in the synovial fluid surrounding prosthetic joints in patients being considered for revision surgery.

30-05-2019 | Rheumatology | News | Article

EULAR publishes recommendations for managing antiphospholipid syndrome

Evidence-based recommendations for the management of antiphospholipid syndrome in adult patients have been issued by EULAR.

28-05-2019 | Rheumatology | News | Article

Predictors of rituximab response identified in patients with SLE

A real-world study of patients with systemic lupus erythematosus suggests that those with more active disease and minimal previous immunosuppressive treatment are most likely to benefit from single-course treatment with rituximab.

24-05-2019 | Rheumatology | News | Article

Opioids, SSRIs, glucocorticoids implicated in RA fracture risk

US research shows that the use of opioids, selective serotonin reuptake inhibitors, or glucocorticoids may increase the risk for all types of osteoporotic fracture in patients with rheumatoid arthritis.

22-05-2019 | Rheumatology | News | Article

Comorbidities linked to worse physical function in psoriatic arthritis patients

Psoriatic arthritis patients with multiple comorbidities have worse physical function than those with just one comorbidity, according to a cross-sectional analysis of the CARMA study of patients from daily clinical practice in Spain.

21-05-2019 | Rheumatology | News | Article

Short-term JAK inhibitor use not linked to increased CV risk

Rheumatoid arthritis patients receiving Janus kinase inhibitors may not be at increased risk for cardiovascular events in the short term, suggests a meta-analysis of randomized controlled trials comparing the active agents with placebo.

20-05-2019 | Rheumatology | News | Article

Glucocorticoid use may increase infection risk in RA patients undergoing joint replacement

Analysis of two US administrative databases indicates that glucocorticoid use is associated with a dose-dependent increase in postoperative infection risk in patients with rheumatoid arthritis undergoing elective total knee or hip replacement.

20-05-2019 | Rheumatology | News | Article

Nintedanib slows lung function decline in SSc-associated interstitial lung disease

Findings from the SENSCIS trial indicate that the tyrosine kinase inhibitor nintedanib reduces the annual rate of decline in forced vital capacity among patients with systemic sclerosis-associated interstitial lung disease.

17-05-2019 | Rheumatology | News | Article

More than two infliximab escalations may be unwarranted in RA

The clinical benefit of infliximab dose escalation in people with rheumatoid arthritis may be limited to the initial two escalations, US study findings indicate.

16-05-2019 | Rheumatology | News | Article

Insights given into TNFi treatment patterns for patients with PsA

Patients initiating their first tumor necrosis factor inhibitor for psoriatic arthritis have a longer time to discontinuation and are less likely to switch treatment than those previously treated with a drug from the same class, say researchers.

Image Credits